The price of Sangamo Therapeutics Inc. (NASDAQ:SGMO) shares last traded on Wall Street fell -2.66% to $1.28.
Based on available information, 11 analysts follow Sangamo Therapeutics Inc. (NASDAQ:SGMO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $16.00 and a low of $1.50, we find $8.00. Given the previous closing price of $1.32, this indicates a potential upside of 506.06 percent. SGMO stock price is now -0.03% away from the 50-day moving average and -48.71% away from the 200-day moving average. The market capitalization of the company currently stands at $201.60M.
Among analysts, 2 rate the stock a hold while 7 rate it a buy. Brokers who have rated the stock have averaged $7.38 as their price target over the next twelve months.
With the price target reduced from $5 to $1.50, BofA Securities Downgraded its rating from Neutral to Underperform for Sangamo Therapeutics Inc. (NASDAQ: SGMO).
In other news, BIOGEN INC., 10% Owner sold 100,000 shares of the company’s stock on Aug 30. The stock was sold for $526,520 at an average price of $5.27. Upon completion of the transaction, the 10% Owner now directly owns 23,652,466 shares in the company, valued at $30.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 29, 10% Owner BIOGEN INC. sold 400,000 shares of the business’s stock. A total of $2,130,720 was realized by selling the stock at an average price of $5.33. This leaves the insider owning 23,752,466 shares of the company worth $30.4 million. Insiders disposed of 633,964 shares of company stock worth roughly $0.81 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SGMO stock. A new stake in Sangamo Therapeutics Inc. shares was purchased by HRT FINANCIAL LP during the first quarter worth $620,000. ACADIAN ASSET MANAGEMENT LLC invested $599,000 in shares of SGMO during the first quarter. In the first quarter, CANDRIAM S.C.A. acquired a new stake in Sangamo Therapeutics Inc. valued at approximately $259,000. PRUDENTIAL FINANCIAL INC acquired a new stake in SGMO for approximately $209,000. PROFUND ADVISORS LLC purchased a new stake in SGMO valued at around $147,000 in the second quarter. In total, there are 255 active investors with 61.50% ownership of the company’s stock.
A candlestick chart of Sangamo Therapeutics Inc. (NASDAQ: SGMO) showed a price of $1.2900 on Tuesday morning. During the past 12 months, Sangamo Therapeutics Inc. has had a low of $1.07 and a high of $6.42. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.90, and a quick ratio of 3.90. The fifty day moving average price for SGMO is $1.2806 and a two-hundred day moving average price translates $2.4783 for the stock.
The latest earnings results from Sangamo Therapeutics Inc. (NASDAQ: SGMO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $0.12, beating analysts’ expectations of -$0.33 by 0.45. This compares to -$0.30 EPS in the same period last year. The net profit margin was -52.80% and return on equity was -40.40% for SGMO. The company reported revenue of $157.96 million for the quarter, compared to $28.23 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 459.52 percent. For the current quarter, analysts expect SGMO to generate $14.83M in revenue.
